These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1929024)

  • 1. Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease.
    Chapman AB; Gabow PA; Schrier RW
    Ann Intern Med; 1991 Nov; 115(10):769-73. PubMed ID: 1929024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease.
    Ecder T; Edelstein CL; Fick-Brosnahan GM; Johnson AM; Chapman AB; Gabow PA; Schrier RW
    Am J Nephrol; 2001; 21(2):98-103. PubMed ID: 11359016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T; Edelstein CL; Chapman AB; Johnson AM; Tison L; Gill EA; Brosnahan GM; Schrier RW
    Nephrol Dial Transplant; 1999 May; 14(5):1113-6. PubMed ID: 10344347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.
    Schrier RW
    Pharmacol Res; 2016 Dec; 114():166-168. PubMed ID: 27794499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute renal failure, renal artery stenosis and angiotensin-converting enzyme (ACE) inhibitor].
    Svarstad E; Hultstrøm D; Jensen D; Jenssen G; Gravendeel J; Iversen BM
    Tidsskr Nor Laegeforen; 2001 Jun; 121(15):1784-8. PubMed ID: 11464681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension and renal injury in experimental polycystic kidney disease.
    Kennefick TM; Al-Nimri MA; Oyama TT; Thompson MM; Kelly FJ; Chapman JG; Anderson S
    Kidney Int; 1999 Dec; 56(6):2181-90. PubMed ID: 10594794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of angiotensin converting enzyme (
    Ramanathan G; Ghosh S; Elumalai R; Periyasamy S; Lakkakula BV
    Indian J Med Res; 2016 Jun; 143(6):748-755. PubMed ID: 27748299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure.
    Mandal AK; Markert RJ; Saklayen MG; Mankus RA; Yokokawa K
    Clin Nephrol; 1994 Sep; 42(3):170-4. PubMed ID: 7994935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion.
    Barendregt JN; Florijn KW; Muizert Y; Chang PC
    Nephrol Dial Transplant; 1995; 10(8):1332-41. PubMed ID: 8538923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Two cases of autosomal dominant polycystic kidney diseases who presented bilateral enlarged kidneys and severe hypertension in the neonatal period].
    Wakaki H; Ikeda M; Hataya H; Ishikura K; Nakashima T; Oosako Y; Honda M
    Nihon Jinzo Gakkai Shi; 2004 Oct; 46(7):719-23. PubMed ID: 15570901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension].
    Klaus D
    Z Kardiol; 1988; 77 Suppl 3():73-88. PubMed ID: 3062960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension in autosomal dominant polycystic kidney disease.
    Chapman AB; Stepniakowski K; Rahbari-Oskoui F
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):153-63. PubMed ID: 20219618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal insufficiency due to angiotensin-converting enzyme inhibitors.
    Toto RD
    Miner Electrolyte Metab; 1994; 20(4):193-200. PubMed ID: 7845322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the ACE gene polymorphism with the progression of autosomal dominant polycystic kidney disease.
    Lee KB; Kim UK; Lee CC
    J Korean Med Sci; 2000 Aug; 15(4):431-5. PubMed ID: 10983692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular risk in polycystic kidney disease].
    Di Lorenzo A; Stallone G; Infante B; Grandaliano G; Schena FP
    G Ital Cardiol (Rome); 2015 Sep; 16(9):479-84. PubMed ID: 26418387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
    Chapman AB; Schrier RW
    Semin Nephrol; 1991 Nov; 11(6):653-60. PubMed ID: 1767138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis.
    Bridoux F; Hazzan M; Pallot JL; Fleury D; Lemaitre V; Kleinknecht D; Vanhille P
    Nephrol Dial Transplant; 1992; 7(2):100-4. PubMed ID: 1314966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.